Role of color Doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy

European Journal of Radiology

Volumn 75, Issue 2, 2010, Pages

  Singh, Gurpreet ^a   Kumar, Pratik ^a   Parshad, Rajinder ^b   Seith, Ashu ^b   Thulkar, Sanjay ^b   Hosten, Norbert ^c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Breast cancer; Chemotherapy; Color Doppler; PI; PSV; RI

Indexed keywords

BLOOD; CHEMOTHERAPY; COLOR; DOPPLER EFFECT; FLOW VELOCITY; HEMODYNAMICS; POLYIMIDES; TUMORS; VELOCITY;

BREAST CANCER; CLINICAL ASSESSMENTS; COLOR DOPPLER; COLOR DOPPLER ULTRASONOGRAPHY; DISEASE FREE SURVIVAL; INFLAMMATORY BREAST CANCERS; NEOADJUVANT CHEMOTHERAPIES; PEAK SYSTOLIC VELOCITIES;

DISEASES;

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77954131226     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.12.027     Document Type: Article

References (23)

1. Kumar A, Singh S, Pradhan S, et al. Doppler ultrasound scoring to predict chemotherapeutic response in advanced breast cancer. World J Surg Oncol 2007;5:99-104.
2. WHOhandbook for reporting results of cancer treatment. Geneva, Switzerland: WHO Offset Publication no. 48; 1979.
3. Oksuzǒlu B, Vural M, Abali H, Yilmaz M, Yildirim N, Zengin N. Blood flow indices by Doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer. Oncology 2006;71:185-9.
4. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma breast carcinoma: Measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 1994;190:825-30.
5. Roubidoux MA, LeCarpentier GL, Fowlkes JB, et al. Sonographic evaluation of early stage breast cancers that undergo neoadjuvant chemotherapy. J Ultrasound Med 2005;24:885-95.
6. Kerimoǧlu U, Akata D, Hazirolan T, et al. Evaluation of radiotherapy response of cervical carcinoma with gray scale and color Doppler ultrasonography: Resistive index correlation with magnetic resonance findings. Diagn Interv Radiol 2006;12:155-60.
7. Huber S, Medl M, Helbich T, et al. Locally advanced breast carcinoma: Computer assisted semi quantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy. J Ultrasound Med 2000;19:601-7.
8. Boonjunwetwat D, Prueksadee J, Sampatanukul P, Chatamra K. Does color Doppler ultrasound vascularity predict the response to neoadjuvant chemotherapy in breast cancer. J Med Assoc Thai 2005;88:1367-72.
9. Yang WT, Tse GM, Lam PK, Metreweli C, Chang J. Correlation between color power Doppler sonographic measurement of breast tumor vasculature and immunohistochemical analysis of microvessel density for the quantitation of angiogenesis. J Ultrasound Med 2002;21:1227-35.
10. Exacoustos C, Zupi E, Cangi B, Chiaretti M, Arduini D, Romanini C. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: An ultrasound, color flow Doppler, hysteroscopic and histological study. Ultrasound Obstet Gynecol 1995;6:435-42.
11. Lee WJ, Chu JS, Huang CS, Chang MF, Chang KJ, Chen KM. Breast cancer vascularity: Color Doppler sonography and histopathology study. Breast Cancer Res Treat 1996;37:291-8.
12. Peters-Engl C, Medl M, Mirau M, et al. Color-coded and spectral Doppler flow in breast carcinomas-relationship with the tumor microvasculature. Breast Cancer Res Treat 1998;47:83-9.
13. Schott AF, Roubidoux MA, Helvie MA, et al. Application of shape analysis to mammographic calcification. IEEE Trans Med Imag 1994;13:263-74.
14. Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A. Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 2005;12:45-51.
15. Fiorentino C, Berruti A, Bottini A, et al. Accuracy of mammography and echography versus clinical palpation in the assessment of the response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 2001;69:143-51.
16. Mankoff DA, Dunnwald LK, Gralow IR, Ellis GK, Drucker MJ, Livingstone RB. Monitoring of response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using Sestamibi scintimammography. Cancer 1999;85:2410-3.
17. Folkman J. Tumor angiogenesis in breast. In: Cancer Medicine. 5th ed. Decker; 2000. Hamilton, pp. 132-152.
18. Morabito A, Sarmiento R, Bonginelli P, Gasparini G. Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol 2004;49:91-107.
19. Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9:43-9.
20. Kurosomi M. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary nodality with pathological complete response (pCR) as endpoint. Breast Cancer 2004;11:139-47, javascript:NewWindow ('000106067.r018').
21. Lagalla R, Caruso G, Finazzo M. Monitoring treatment response with color and power Doppler. Eur J Radiol 1998;27:149-56.
22. Hayashi N, Miyamoto Y, Nakata N, et al. Breast masses: Color Doppler, power Doppler, and spectral analysis findings. J Clin Ultrasound 1998;26:231-8, javascript:NewWindow ('000106067.r014').
23. Peters-Engl C, Medl M, Leodolter S. The use of color-coded and spectral Doppler ultrasound in the differentiation of benign and malignant lesions. Br J Cancer 1995;72:137-9.